Development of lung and muscle protein factories to deliver therapeutic monoclonal antibodies
Recombinant therapeutic proteins, of which monoclonal antibodies (mAbs) represent the largest market, are used to treat diseases including cancer, blood and immune disorders. The cost and complexity of large-scale production and purification of mAbs translates to high cost of therapy. We hypothesise...
Main Authors: | Antepowicz, A, Tan, A, Pringle, A, Hyde, S, Gill, D |
---|---|
פורמט: | Conference item |
יצא לאור: |
Mary Ann Liebert Inc
2016
|
פריטים דומים
-
Development of lung and muscle factories to deliver therapeutic monoclonal antibodies
מאת: Antepowicz, A
יצא לאור: (2018) -
431. Lung antibody factory for passive immunisation against influenza
מאת: Tan, T, et al.
יצא לאור: (2016) -
Lentiviral-mediated expression of monoclonal antibodies in the lung to protect against influenza
מאת: Du, Y, et al.
יצא לאור: (2020) -
Antibody gene transfer for prophylaxis of respiratory syncytial virus (RSV) infection
מאת: Antepowicz, A, et al.
יצא לאור: (2018) -
The lung as a factory to produce secreted intrapulmonary and circulatory proteins
מאת: Paul-Smith, M, et al.
יצא לאור: (2017)